MX2022009818A - Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). - Google Patents
Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp).Info
- Publication number
- MX2022009818A MX2022009818A MX2022009818A MX2022009818A MX2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A
- Authority
- MX
- Mexico
- Prior art keywords
- usp1
- parp
- inhibitors
- ubiquitin
- specific
- Prior art date
Links
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 title abstract 7
- 101710167636 Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 title abstract 7
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title abstract 6
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976864P | 2020-02-14 | 2020-02-14 | |
| US202063032245P | 2020-05-29 | 2020-05-29 | |
| US202163146937P | 2021-02-08 | 2021-02-08 | |
| PCT/US2021/017912 WO2021163530A1 (en) | 2020-02-14 | 2021-02-12 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009818A true MX2022009818A (es) | 2022-09-05 |
Family
ID=77291879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009818A MX2022009818A (es) | 2020-02-14 | 2021-02-12 | Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277533A1 (https=) |
| EP (1) | EP4103165A4 (https=) |
| JP (1) | JP2023514568A (https=) |
| KR (1) | KR20220140732A (https=) |
| CN (1) | CN115066235A (https=) |
| AU (1) | AU2021218805A1 (https=) |
| CA (1) | CA3168009A1 (https=) |
| IL (1) | IL295149A (https=) |
| MX (1) | MX2022009818A (https=) |
| TW (1) | TW202140026A (https=) |
| WO (1) | WO2021163530A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| US20240409538A1 (en) * | 2021-10-19 | 2024-12-12 | Impact Therapeutics (Shanghai), Inc. | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
| IL312642A (en) * | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430049A4 (en) * | 2021-11-12 | 2025-12-17 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| US20250161306A1 (en) * | 2022-01-25 | 2025-05-22 | KSQ Therapeutics, Inc. | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors |
| JP2025531133A (ja) * | 2022-09-20 | 2025-09-19 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体 |
| CA3268518A1 (en) * | 2022-09-23 | 2024-03-28 | KSQ Therapeutics, Inc. | THERAPEUTIC COMBINATIONS INCLUDING UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS (USP1) AND SELECTIVE PARP1 INHIBITORS |
| CN117384187B (zh) * | 2022-09-30 | 2026-01-30 | 轩竹生物科技股份有限公司 | 泛素特异性蛋白酶1抑制剂 |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| CN121866064A (zh) * | 2023-06-16 | 2026-04-14 | 韩国科学技术研究院 | 包含BRCA特异性siRNA作为活性成分的用于预防或治疗靶向癌症的药物组合物 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025087460A1 (zh) * | 2023-10-25 | 2025-05-01 | 海思科医药集团股份有限公司 | 一种吡啶并吡唑衍生物药物组合物及其应用 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| TW202539659A (zh) | 2024-01-10 | 2025-10-16 | 美商維瑞斯治療股份有限公司 | Ｄｎａ損傷修復途徑的新穎抑制劑 |
| WO2025153067A1 (zh) * | 2024-01-19 | 2025-07-24 | 江苏亚虹医药科技股份有限公司 | Usp1抑制剂及其医药用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025180502A1 (zh) * | 2024-03-01 | 2025-09-04 | 上海齐鲁制药研究中心有限公司 | 一种联合用药物组合物及其用途 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| GB201519573D0 (en) * | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| US11485736B2 (en) * | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
| WO2021163530A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
-
2021
- 2021-02-12 WO PCT/US2021/017912 patent/WO2021163530A1/en not_active Ceased
- 2021-02-12 MX MX2022009818A patent/MX2022009818A/es unknown
- 2021-02-12 US US17/904,159 patent/US20230277533A1/en not_active Abandoned
- 2021-02-12 KR KR1020227027461A patent/KR20220140732A/ko active Pending
- 2021-02-12 CA CA3168009A patent/CA3168009A1/en active Pending
- 2021-02-12 JP JP2022548896A patent/JP2023514568A/ja active Pending
- 2021-02-12 AU AU2021218805A patent/AU2021218805A1/en active Pending
- 2021-02-12 IL IL295149A patent/IL295149A/en unknown
- 2021-02-12 EP EP21754160.6A patent/EP4103165A4/en not_active Withdrawn
- 2021-02-12 CN CN202180013564.7A patent/CN115066235A/zh active Pending
- 2021-02-17 TW TW110105371A patent/TW202140026A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL295149A (en) | 2022-09-01 |
| KR20220140732A (ko) | 2022-10-18 |
| US20230277533A1 (en) | 2023-09-07 |
| EP4103165A4 (en) | 2024-02-28 |
| TW202140026A (zh) | 2021-11-01 |
| CN115066235A (zh) | 2022-09-16 |
| WO2021163530A1 (en) | 2021-08-19 |
| EP4103165A1 (en) | 2022-12-21 |
| AU2021218805A1 (en) | 2022-09-01 |
| JP2023514568A (ja) | 2023-04-06 |
| CA3168009A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009818A (es) | Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). | |
| PH12021551402A1 (en) | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| ZA202503575B (en) | Novel prmt5 inhibitor and use thereof | |
| MX2023011576A (es) | Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos. | |
| US9957270B2 (en) | Fused pyrimidine-based hydroxamate derivatives | |
| MY199409A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| MX2025004107A (es) | Inhibidores heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos | |
| RU2763346C2 (ru) | Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы | |
| MX2025003321A (es) | Combinaciones terapeuticas que comprenden inhibidores de la proteasa de procesamiento especifica de ubiquitina 1 (usp1) e inhibidores selectivos de parp1 | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| MX2025003908A (es) | Compuesto inhibidor de parg | |
| MY209389A (en) | Use of bi853520 in cancer treatment | |
| SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
| IL165264A0 (en) | Protein kinase inhibitors | |
| NZ514450A (en) | Use of dipeptidyl peptidase IV inhibitors for promoting growth | |
| ZA202404839B (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| MX2024012225A (es) | Combinaciones terapeuticas que comprenden inhibidores de la proteasa de procesamiento de ubiquitina especifica 1 (usp1) y agentes quimioterapeuticos | |
| MXPA05003104A (es) | Hidromorfonas n-sustituidas y uso de las mismas. | |
| PH12021551319A1 (en) | Methods for treating cancer resistant to cdk4/6 inhibitors | |
| IL314308A (en) | Ubiquitin-specific processing protease 1 (USP1) inhibitors for the treatment of solid tumors | |
| MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
| ZA202406390B (en) | Compounds and their use in treating cancer | |
| MX2026000842A (es) | Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de la glutaminil-peptido ciclotransferasa y proteina similar a glutaminil-peptido ciclotransferasa | |
| CR20240394A (es) | Inhibidores de proteínas de unión a emopamilo y usos de estos | |
| NO963463L (no) | Middel for profylakse og behandling av tromboksan A2-medierte sykdommer |